High Purity 99% Cagrilintide Synthetic Peptide 5/10/20mg Research Raw Material Fast Delivery
62 Inquiries
1415456-99-3
Laboratory Grade
99%
SHENZHEN
5/10/20mg*10vials
2026-07-25
Polypeptide Products
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Cagrilintide is a long-acting amylin analog and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Cagrilintide is characterized by its peptide structure and amylin receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.
Basic Info-
Product Name:
Cagrilintide
Other Name:Cagrilintide;Cargliptin;Caglitide;Cagrilintide acetate;Cagrilintide peptide;Cagrilintide 5mg 10mg 15mg;Cagrilintide(Acetate form);Kagliptin
CAS No.:1415456-99-3
Molecular Weight:0
EC Number:206-141-6
Color/Form:White to off-white
Categories:
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Polypeptide Products
-
Location:
No. 917, 9th Floor, Unit 1, Building 19, Shengshi Huayuan Business Center, Shunhua Road Sub-district, High-tech Zone, Jinan City, Shandong Province
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Inquiry History62 Inquiries
Country Product Purchase Quantity Date Posted 
Australia
Cagrilintide
20 MG Aug 17, 2026 
United Kingdom
Cagrilintide
10 MG Jul 31, 2026 
France
Cagrilintide
10 MG May 22, 2026
Australia
Cagrilintide
4 MT Mar 9, 2026 
United States
Cagrilintide
15 MG Feb 25, 2026
United States
Cagrilintide
10 PCS Dec 27, 2025
United States
Cagrilintide
2 MT Dec 21, 2025
United States
Cagrilintide
100 MG Oct 28, 2025
United States
cagrilintide
2 MT Aug 8, 2025 
Philippines
Retatrutide
5 MG Aug 5, 2025 
China
Cagrilintide
100 G May 6, 2025
United States
cagrilintide
5 MG Feb 18, 2025
United States
Cagrilintide
3 MT Feb 7, 2025
United States
Cagrilintide
100 Nov 12, 2024
United States
Cagrillintide Lyophilized powder
100 MG Jul 4, 2024
United States
Cagrillintide Lyophilized powder
1000 MG Apr 20, 2024
United States
Cagrilintide
25 MG Aug 31, 2026
United States
Cagrlintide
1 MT Jul 31, 2026
United Kingdom
cagrilintrude
20 MG Jul 21, 2026
United States
Cagrilintide
1 KG Jul 17, 2026 Post an enquiry for this product
